FY2025 Earnings Estimate for CLDX Issued By Leerink Partnrs

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Celldex Therapeutics in a research note issued to investors on Monday, November 10th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will earn ($3.60) per share for the year, down from their prior forecast of ($3.45). The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics' Q4 2025 earnings at ($0.93) EPS, FY2026 earnings at ($4.87) EPS, FY2027 earnings at ($5.73) EPS, FY2028 earnings at ($5.09) EPS and FY2029 earnings at $0.36 EPS.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.

Several other brokerages have also commented on CLDX. Weiss Ratings reiterated a "sell (d-)" rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Mizuho began coverage on Celldex Therapeutics in a research report on Tuesday, October 21st. They set an "outperform" rating and a $48.00 price objective for the company. HC Wainwright cut their price objective on Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating on the stock in a research note on Wednesday, August 20th. Wells Fargo & Company cut their price target on Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a report on Wednesday, August 20th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $62.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

Read Our Latest Stock Analysis on CLDX

Celldex Therapeutics Price Performance

CLDX stock traded down $0.02 during trading on Thursday, hitting $24.23. The stock had a trading volume of 133,419 shares, compared to its average volume of 1,015,047. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $29.05. The company's 50-day moving average price is $25.49 and its two-hundred day moving average price is $22.82. The stock has a market capitalization of $1.61 billion, a P/E ratio of -8.07 and a beta of 1.36.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Celldex Therapeutics by 0.4% during the first quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company's stock worth $70,757,000 after buying an additional 16,440 shares in the last quarter. Commodore Capital LP increased its stake in Celldex Therapeutics by 7.8% during the 2nd quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company's stock valued at $70,208,000 after purchasing an additional 250,000 shares in the last quarter. Bellevue Group AG boosted its holdings in shares of Celldex Therapeutics by 7.7% during the 2nd quarter. Bellevue Group AG now owns 3,307,569 shares of the biopharmaceutical company's stock valued at $67,309,000 after acquiring an additional 235,954 shares during the last quarter. Vestal Point Capital LP lifted its stake in shares of Celldex Therapeutics by 781.0% in the 2nd quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company's stock worth $35,612,000 after purchasing an additional 1,551,354 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Celldex Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 1,672,980 shares of the biopharmaceutical company's stock worth $34,050,000 after buying an additional 83,174 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

See Also

• Five stocks we like better than Celldex Therapeutics
• How to Capture the Benefits of Dividend Increases
• 4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive
• 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
• Oklo’s Meltdown Is Over: A Robust Rebound Lies Ahead
• Breakout Stocks: What They Are and How to Identify Them
• 3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Celldex Therapeutics Right Now?

Before you consider Celldex Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.

While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here